{"id":6544,"date":"2024-06-03T16:01:19","date_gmt":"2024-06-03T20:01:19","guid":{"rendered":"https:\/\/bridgebio.local\/news\/auto-draft\/"},"modified":"2024-06-03T11:46:49","modified_gmt":"2024-06-03T15:46:49","slug":"achondroplasia-investor-call","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/","title":{"rendered":"BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024"},"content":{"rendered":"<p><b><span data-contrast=\"auto\">PALO ALTO, CA \u2013 June 3, 2024 \u2014<\/span><\/b><span data-contrast=\"auto\"> BridgeBio Pharma, Inc. <\/span><span data-contrast=\"auto\">(Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases,<\/span><span data-contrast=\"none\"> today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children\u2019s Research Institute in Melbourne, Australia, and the global lead investigator for PROPEL 2, will host a call on June 4, 2024, at 8:00 am ET to share results from Month 12 and Month 18 from Cohort 5 of PROPEL 2, a Phase 2 trial of the investigational oral therapy infigratinib in children with achondroplasia.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">To access the live webcast, please visit the \u201cEvents\u201d page within the Investors section of the BridgeBio website at <\/span><a href=\"https:\/\/investor.bridgebiodev.wpengine.com\/\"><b><span data-contrast=\"none\">http:\/\/investor.bridgebiodev.wpengine.com<\/span><\/b><\/a><span data-contrast=\"none\">. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">About BridgeBio Pharma, Inc.<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit\u202f<\/span><a href=\"http:\/\/www.bridgebio.local\/\"><b><span data-contrast=\"none\">bridgebiodev.wpengine.com<\/span><\/b><\/a><span data-contrast=\"none\">\u202fand follow us on\u202f<\/span><a href=\"https:\/\/www.linkedin.com\/company\/bridgebio\/\"><b><span data-contrast=\"none\">LinkedIn<\/span><\/b><\/a><span data-contrast=\"none\">\u202fand\u202f<\/span><a href=\"https:\/\/twitter.com\/BridgeBioPharma\"><b><span data-contrast=\"none\">Twitter<\/span><\/b><\/a><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"none\">BridgeBio Contact:<\/span><\/b><br \/>\n<span data-contrast=\"none\">Vikram Bali<\/span><br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fugVVwAx1GYYTInBeTohYDy4FLEcn5zgfziCScXYuDM_iXkWjOkg3QygLNq5Q7gd5LneNVpma5M7gKAxmAefYpFajTkwnRTdm371CnV3i-E=\"><b><span data-contrast=\"none\">contact@bridgebiodev.wpengine.com<\/span><\/b><\/a><br \/>\n<span data-contrast=\"none\">(650)-789-8220<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, CA \u2013 June 3, 2024 \u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children\u2019s Research Institute in Melbourne, Australia, and the global lead investigator for PROPEL 2, will host a [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-6544","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":{"people":false,"external_link":"","presentation":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 - BridgeBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 - BridgeBio\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, CA \u2013 June 3, 2024 \u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children\u2019s Research Institute in Melbourne, Australia, and the global lead investigator for PROPEL 2, will host a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-03T20:01:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-03T15:46:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Holly Condon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Holly Condon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/\",\"url\":\"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/\",\"name\":\"BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 - BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2024-06-03T20:01:19+00:00\",\"dateModified\":\"2024-06-03T15:46:49+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca\"},\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca\",\"name\":\"Holly Condon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g\",\"caption\":\"Holly Condon\"},\"url\":\"https:\/\/bridgebio.com\/author\/hcondon\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 - BridgeBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 - BridgeBio","og_description":"PALO ALTO, CA \u2013 June 3, 2024 \u2014 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children\u2019s Research Institute in Melbourne, Australia, and the global lead investigator for PROPEL 2, will host a [&hellip;]","og_url":"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/","og_site_name":"BridgeBio","article_published_time":"2024-06-03T20:01:19+00:00","article_modified_time":"2024-06-03T15:46:49+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Holly Condon","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Holly Condon","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/","url":"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/","name":"BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 - BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2024-06-03T20:01:19+00:00","dateModified":"2024-06-03T15:46:49+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca"},"breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/achondroplasia-investor-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca","name":"Holly Condon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g","caption":"Holly Condon"},"url":"https:\/\/bridgebio.com\/author\/hcondon\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/6544"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=6544"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/6544\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=6544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=6544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=6544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}